

Date: 21 June 2022

BY EMAIL ONLY

The Listing Division
The Stock Exchange of Hong Kong Limited
11/F., One International Finance Centre
1 Harbour View Street
Central
Hong Kong

Attn.: Mr. Max Cheng / Mr. Charlie Wong / Mr. Matthew Leung

Dear Sirs,

Company : **China NT Pharma Group Company Limited**
中國泰凌醫藥集團有限公司

Stock Code : **1011**

Subject : Profit Forecast – Confirmation Letter under the Requirements of Rule 14.62(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)

Reference is made to the announcement of the Company dated 21 June 2022 in relation to, among others, (i) the Transaction Documents and the transactions contemplated thereunder; and (ii) the valuation report of the Commercialisation Rights as of 31 May 2022 (the “**Valuation Report**”) prepared by CHFT Advisory and Appraisal Ltd. (the “**Valuer**”), which adopted the income approach in the valuation (the “**Announcement**”). Unless otherwise stated herein, capitalised terms in this letter shall have the same meaning as defined in the Announcement.

The board of directors (the “**Board**”) of the Company has reviewed the bases and assumptions of the valuation and discussed the same with the Valuer.

Pursuant to the requirements of Rule 14.62(3) of the Listing Rules, the Board confirmed that the above profit forecast used in the Valuation Report has been made after due and careful enquiry.

By Order of the Board
China NT Pharma Group Company Limited



Ng Tit
Chairman

Date: 23 August 2022

BY EMAIL ONLY

The Listing Division
Hong Kong Exchanges and Clearing Limited
12/F, Two Exchange Square
8 Connaught Place, Central
Hong Kong
Attn.: Mr. Max Cheng / Mr. Charlie Wong / Mr. Matthew Leung

Dear Sirs,

Company : China NT Pharma Group Company Limited
中國泰凌醫藥集團有限公司

Stock Code : 1011

Subject : Profit Forecast – Confirmation Letter under the Requirements of Rule 14.62(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)

Reference is made to the circular of the Company dated 23 August 2022 (the “**Circular**”) in relation to, among others, (i) the Transaction Documents and the transactions contemplated thereunder; and (ii) the valuation report of the Commercialisation Rights for purchase price allocation purpose as of 31 May 2022 (the “**Valuation**”) as set out in section 9 of the valuation report in the Appendix III to the Circular prepared by CHFT Advisory and Appraisal Ltd. (the “**Valuer**”), which adopted the income approach in the Valuation. Unless otherwise stated herein, capitalised terms in this letter shall have the same meaning as defined in the Circular.

The board of directors (the “**Board**”) of the Company has reviewed the bases and assumptions of the Valuation and discussed the same with the Valuer.

Pursuant to the requirements of Rule 14.62(3) of the Listing Rules, the Board confirmed that the above profit forecast used in the Valuation has been made after due and careful enquiry.

By Order of the Board
China NT Pharma Group Company Limited



Ng Tit
Chairman